A study Comparing the Epigenome of Centenarians and Newborns, Awarded by Diario Médico
News Nov 22, 2012
IDIBELL has received one of the awards for the Best Ideas of the Year, awarded by the publication specializing in medicine and health Diario Médico, by a study concluding that epigenetic marks are degrading over time. The research, which compares the epigenome of centenarians and newborns, was published in June 2012 in the journal Proceedings of the National Academy of Sciences (PNAS). The work has been coordinated by the Director of the Epigenetics and Cancer Biology Program of IDIBELL, Manel Esteller.
While the genome of all cells in the human body, regardless of its appearance and function, is identical, chemical signals that regulate it, known as epigenetic marks, are specific to each human tissue and organ. The surprising result of the work made by Dr. Esteller group is that, even for the same tissue or organ, the epigenome varies depending on the age of the person. The study has shown that the epigenome of a centenarian is altered.
Gala at the National Theatre
The award was presented on November 19 at a gala at the National Theatre of Catalonia. The award was collected by the first author of the paper, the researcher of the Cancer Epigenetics group at IDIBELL Holger A Heyn.
In addition to this award for the IDIBELL research, the Bellvitge University Hospital received an award for the Hospital Efficiency Program, for the centralized management of waiting lists and surgical areas. The initiative has reduced surgical waiting lists and has rescheduled the operating rooms.
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.READ MORE
Scientists report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP). The strategy could one day be used to slow or prevent vision loss in people with the disease. NEI is part of the National Institutes of Health.